Drug intelligence / Profile preview

Clatazev

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

Clatazev is a 60 mg film-coated tablet containing Daclatasvir, an antiviral medication developed by Bristol-Myers Squibb. It is used in combination with other antiviral agents for the treatment of chronic hepatitis C virus (HCV) infection. Daclatasvir works by inhibiting the non-structural protein 5A (NS5A) of the hepatitis C virus, which is crucial for viral RNA replication and virion assembly.

Brand names: Clatazev

Targets

NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on Clatazev.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clatazev.

Explore the full profile